1-20 of 1,954 results for subject:MRSA
Librarians' tools
- Search time
- 0.302 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:MRSA
- We searched for
- subject_t:MRSA OR subject_t:"Methicillin resistant staphylococcus aureus" OR subject_ses:11632
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...
Lords question for short debate on what assessment they have made of the risks of antimicrobial resistance.
Lords question for short debate on what assessment they have made of the risks of antimicrobial resistance.
To ask the Secretary of State for Health, how many hospital-borne cases of MRSA were recorded in England in (a) 2000, (b) 2005, (c) 2010 and (d) 2015.
To ask the Secretary of State for Health, how many hospital-borne cases of MRSA were recorded in England in (a) 2000, (b) 2005, (c) 2010 and (d) 2015.
In April 2013 Public Health England took over the surveillance of methicillin-resistant staphylococcus aureus (MRSA) bacteraemia, formerly undertaken by the Health Protection Agency. We do not hold the data for 2000 and 2005.
Cases are published according to both trust apportionment and trust assignment. For the purpose of answering this question trust apportionment or assignment can be considered as “hospital borne” cases.
The assignment process was added to the MRSA surveillance in 2013 superseding the previously used apportionment method. The assignment process utilises individual case review and therefore allows for a much more considered categorisation of a case and associated learning to prevent similar cases occurring in the future, than was previously possible. The assignment process was only introduced in 2013 as MRSA numbers were previously considered to be too high to make this resource demanding method viable.
The total number of trust apportioned and trust assigned cases are displayed in Tables 1 and 2 respectively.
Table 1: Trust apportioned counts of MRSA bacteraemia in 2008, 2010 and 2015.
April 2008 to March 2009 | April 2010 to March 2011 | April 2015 to March 2016 |
1,606 | 688 | 297 |
Table 2: Trust assigned counts of MRSA bacteraemia in 2015.
April 2015 to March 2016 |
302 |
Notes:
- Cases are published on a financial year basis.
- Trust apportioned data are not available for the years 2000 and 2005.
- Trust assigned are not available for the years 2000, 2005 and 2010.
- Cases are deemed to be Trust apportioned if the following criteria are met:-
- The location where the specimen was taken is given as ‘acute trust’ or is not known;
- The patient was either an ‘In-patient’, ‘Day-patient’, in ‘Emergency assessment’ or is not known.
- Patient’s specimen date is on, or after, the third day of the admission (or admission date is null), where the day of admission is day 1.
- Cases are deemed to be trust assigned on the basis of Post Infection Review (PIR) assignment and relevant cases are assigned to acute trusts.
- The trust assignment method supersedes the apportionment one post 2013 and utilises case review by the teams caring for the patient.
Letter dated 04/02/2016 from Ben Gummer MP to Nigel Mills MP regarding the hand hygiene debate and rates of MRSA, MSSA, C. diff and E. coli. 1 p.
Letter dated 04/02/2016 from Ben Gummer MP to Nigel Mills MP regarding the hand hygiene debate and rates of MRSA, MSSA, C. diff and E. coli. 1 p.
To ask the Minister for the Cabinet Office how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period.
[151061]
To ask the Minister for the Cabinet Office how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period.
[151061]
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the authority to reply.
Letter from Glen Watson, dated March 2013:
As Director General for the Office for National Statistics, I have been asked to reply to your recent question to the Secretary of State for Health asking how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period. [151061]
In 2011 (the latest available year) there were 53 deaths in hospitals in England where the underlying cause was MRSA and a further 279 where MRSA was shown on the death certificate as a contributory factor. In the same period, there were 230,819 deaths in hospitals in England.1
Further information on deaths involving MRSA is available at the link below. The next edition of the MRSA bulletin, based on 2012 data, is due to be published in August 2013.
http://www.ons.gov.uk/ons/rel/subnational-health2/deaths-involving-mrsa/2007-to-2011/index.html
Annual report of the Chief Medical Officer. Volume Two, 2011: infections and the rise of antimicrobial resistance. 154 p.
Annual report of the Chief Medical Officer. Volume Two, 2011: infections and the rise of antimicrobial resistance. 154 p.
Table showing numbers of cases of MRSA bacteraemia, Clostridium difficile (CDI), and MSSA bacteraemia for England, by NHS Trust, April 2009 to March 2012. 17 p.
Table showing numbers of cases of MRSA bacteraemia, Clostridium difficile (CDI), and MSSA bacteraemia for England, by NHS Trust, April 2009 to March 2012. 17 p.
To ask the Secretary of State for Health how many patients contracted (a) MRSA and (b) other hospital-acquired infections in NHS hospitals in each NHS hospital trust in England and Wales in each of the last three years.
[131612]
To ask the Secretary of State for Health how many patients contracted (a) MRSA and (b) other hospital-acquired infections in NHS hospitals in each NHS hospital trust in England and Wales in each of the last three years.
[131612]
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections and C. difficile infections are at their lowest levels since mandatory surveillance began. Compared to the 12 months to May 2010, the latest annual data show that MRSA bloodstream infections have fallen by 48% and C. difficile infections by 38%.
Data on health care associated infections in Wales are collated and published by the Welsh Healthcare Associated Infection Programme. Information on all health care associated infections covering England is not collected routinely by the Health Protection Agency. However, the agency does collect data on specific health care associated infections in England, such as MRSA bacteraemia, Clostridium difficile infection, and Methicillin sensitive Staphylococcus aureus bacteraemia, that are detected and reported by an acute NHS Trust laboratory.
The information on these infections has been placed in the Library.
To ask Her Majesty’s Government what assessment they have made of the progress towards eliminating methicillin-resistant staphylococcus aureus (MRSA) infections in hospitals.
To ask Her Majesty’s Government what assessment they have made of the progress towards eliminating methicillin-resistant staphylococcus aureus (MRSA) infections in hospitals.
I. Table showing MRSA bloodstream infections in Berkshire NHS Trusts from 2001/02 to 2009/10. II. Table showing surgical site infections in Berkshire NHS Trusts, April 2004 to 2010. III. Table showing clostridium difficile infections in Berkshire NHS Trusts, 2004 to 2010.
I. Table showing MRSA bloodstream infections in Berkshire NHS Trusts from 2001/02 to 2009/10. II. Table showing surgical site infections in Berkshire NHS Trusts, April 2004 to 2010. III. Table showing clostridium difficile infections in Berkshire NHS Trusts, 2004 to 2010.
To ask the Secretary of State for Health what tests are available to detect (a) MRSA and (b) clostridium difficile infection; and by what means such tests are deployed in the NHS.
To ask the Secretary of State for Health what tests are available to detect (a) MRSA and (b) clostridium difficile infection; and by what means such tests are deployed in the NHS.
To ask the Secretary of State for Health what recent progress has been made on the deployment in the NHS of new tests for (a) MRSA and (b) clostridium difficile; and what steps he is taking to ensure the deployment in the NHS of the most accurate, rapid and cost-effective...
To ask the Secretary of State for Health what recent progress has been made on the deployment in the NHS of new tests for (a) MRSA and (b) clostridium difficile; and what steps he is taking to ensure the deployment in the NHS of the most accurate, rapid and cost-effective...
Lords statement on hospital trusts in Essex and patient safety in the NHS.
Lords statement on hospital trusts in Essex and patient safety in the NHS.